Arecor Therapeutics plc

LSE AREC.L

Arecor Therapeutics plc Free Cash Flow Yield on January 24, 2025: -27.66%

Arecor Therapeutics plc Free Cash Flow Yield is -27.66% on January 24, 2025, a -196.29% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Arecor Therapeutics plc 52-week high Free Cash Flow Yield is -9.55% on February 01, 2024, which is 65.48% above the current Free Cash Flow Yield.
  • Arecor Therapeutics plc 52-week low Free Cash Flow Yield is -29.05% on December 20, 2024, which is -5.04% below the current Free Cash Flow Yield.
  • Arecor Therapeutics plc average Free Cash Flow Yield for the last 52 weeks is -16.47%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
SV Wall Street
LSE: AREC.L

Arecor Therapeutics plc

CEO Dr. Sarah Jennifer Howell Ph.D.
IPO Date June 3, 2021
Location United Kingdom
Headquarters Chesterford Research Park
Employees 50
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Similar companies

POLB.L

Poolbeg Pharma PLC

USD 0.07

-3.12%

StockViz Staff

January 30, 2025

Any question? Send us an email